EnteroTrack, LLC — SEC Form D Filing

EnteroTrack, LLC filed an SEC Form D on September 25, 2026 in Medical Devices.

Form D filing details

Filing
SEC Form D
Filing date
September 25, 2026
Round stage
Seed
Industry
Medical Devices
Website
https://enterotrack.com/

Problem

Patients with Eosinophilic Esophagitis (EoE) require monitoring of their disease activity and inflammatory response, but traditional methods like repeated endoscopies are invasive, costly, and often require anesthesia.

Solution

EnteroTrack offers the Esophageal String Test® (EST) and the EnteroTracker®, a minimally invasive, non-endoscopic tool that collects samples from the esophagus to monitor EoE activity and provide biomarker-based insights into mucosal inflammation.

Why now

There is a growing demand for less invasive and more patient-friendly diagnostic and monitoring tools in chronic disease management, especially for conditions like EoE that require frequent assessment. Advances in biomarker analysis also enable this type of non-endoscopic sampling.

Verdict

Investors backed this seed stage company on the promise of displacing an established, uncomfortable procedure with a more patient-friendly alternative for a growing chronic condition. This cleared because it offered a clear patient-centric improvement over existing practice, not because it introduced a novel diagnostic modality. The implicit bet was on rapid clinical adoption driven by patient preference and physician relief from repeat endoscopy burden, but the upside was limited by the relatively niche initial application despite a broad "minimally invasive" trend.

Source: SEC EDGAR Form D filing